Fmr LLC held its stake in shares of Axovant Sciences Ltd. (NYSE:AXON) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 677,170 shares of the biotechnology company’s stock at the end of the first quarter. Fmr LLC’s holdings in Axovant Sciences were worth $10,117,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Norges Bank bought a new position in Axovant Sciences during the fourth quarter valued at $508,000. AQR Capital Management LLC bought a new position in Axovant Sciences during the fourth quarter valued at $139,000. Woodstock Corp boosted its position in Axovant Sciences by 55.0% in the first quarter. Woodstock Corp now owns 35,003 shares of the biotechnology company’s stock valued at $523,000 after buying an additional 12,417 shares during the period. Nationwide Fund Advisors boosted its position in Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock valued at $1,248,000 after buying an additional 34,654 shares during the period. Finally, Teachers Advisors LLC boosted its position in Axovant Sciences by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 2,038 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.
Axovant Sciences Ltd. (NYSE:AXON) opened at 23.20 on Tuesday. The company’s market capitalization is $2.49 billion. Axovant Sciences Ltd. has a 12 month low of $11.01 and a 12 month high of $26.49. The firm’s 50-day moving average is $22.78 and its 200-day moving average is $18.23.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.02. Equities analysts anticipate that Axovant Sciences Ltd. will post ($2.20) EPS for the current fiscal year.
WARNING: “Axovant Sciences Ltd. (NYSE:AXON) Position Maintained by Fmr LLC” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/25/axovant-sciences-ltd-nyseaxon-position-maintained-by-fmr-llc.html.
Several research firms recently weighed in on AXON. Oppenheimer Holdings, Inc. upped their price objective on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a research report on Monday, April 17th. CIBC upped their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 14th. Jefferies Group LLC restated a “buy” rating and issued a $31.00 price objective on shares of Axovant Sciences in a research report on Tuesday, April 18th. Cowen and Company restated an “outperform” rating and issued a $30.00 price objective (up from $22.00) on shares of Axovant Sciences in a research report on Tuesday, June 13th. Finally, Zacks Investment Research cut shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Axovant Sciences presently has a consensus rating of “Buy” and a consensus price target of $28.50.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
